Free Newsletter
Celiac disease vax has positive Ph1 results
Sufferers from celiac disease may get a reprieve from their gluten-free diets thanks to a vaccine currently in Phase I trials. But the vaccine won't go into Phase II until next year at the earliest, and most likely won't be available to the public until 2017.
In an Australian study, patients receiving weekly doses of ImmusanT's Nexvax2 while on a strict gluten-free diet showed symptoms similar to those of eating gluten. Scientists say this shows they are targeting the right peptides that could help sufferers eventually tolerate gluten.
"The gluten free diet is very difficult, it's costly, it's complex," said Dr. Jason Tye-Din to Dietsinreview. "Unfortunately even people who follow it very well--there's a large proportion who still don't get full healing of their bowel, so alternatives to the gluten free diet are really needed at the moment."
Researchers hope the vaccine will enter Phase II trials early next year, and they believe the vaccine could treat up to 90 percent of celiac disease patients.
- check out the release
- and here's more from the International Business Times
Related Articles:
Mouse-human study IDs celiac disease triggers
VCs invest $21.5M in Alvine's celiac drug program
Comments
Do they expect it to also help people who have severe sensitivities to gluten or just persons who have been diagnosed with celiac disease?
- reply
You raise a key point, since there are many more people with gluten sensitivity that with a fully-diagnosed case of celiac. The current research increasingly points to a spectrum of conditions ranging from gluten sensitivity to celiac disease. My take on this is that "gluten sensitivity" is quite distinct from celiac, involving the "innate" immune sustems, so I would not expect the "vaccine" to affect this.
I have a couple of blog posts addressing this topic, and would appreciate your comments:
http://bit.ly/hgIN2B
http://bit.ly/jIGG2E
- reply
Post a comment
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: